Abstract Background Overcoming spaceflight-induced (patho)physiologic adaptations is a major challenge preventing long-term deep space exploration. RNA interference (RNAi) has emerged as a promising therapeutic for combating diseases on Earth; however the efficacy of RNAi in space is currently unknown. Methods Caenorhabditis elegans were prepared in liquid media on Earth using standard techniques and treated acutely with RNAi or a vector control upon arrival in Low Earth Orbit. After culturing during 4 and 8 d spaceflight, experiments were stopped by freezing at −80°C until analysis by mRNA and microRNA array chips, microscopy and Western blot on return to Earth. Ground controls (GC) on Earth were simultaneously grown under identical conditions. Results After 8 d spaceflight, mRNA expression levels of components of the RNAi machinery were not different from that in GC (e.g., Dicer, Argonaute, Piwi; P>0.05). The expression of 228 microRNAs, of the 232 analysed, were also unaffected during 4 and 8 d spaceflight (P>0.05). In spaceflight, RNAi against green fluorescent protein (gfp) reduced chromosomal gfp expression in gonad tissue, which was not different from GC. RNAi against rbx-1 also induced abnormal chromosome segregation in the gonad during spaceflight as on Earth. Finally, culture in RNAi against lysosomal cathepsins prevented degradation of the muscle-specific α-actin protein in both spaceflight and GC conditions. Conclusions Treatment with RNAi works as effectively in the space environment as on Earth within multiple tissues, suggesting RNAi may provide an effective tool for combating spaceflight-induced pathologies aboard future long-duration space missions. Furthermore, this is the first demonstration that RNAi can be utilised to block muscle protein degradation, both on Earth and in space.

Citation: Etheridge T, Nemoto K, Hashizume T, Mori C, Sugimoto T, Suzuki H, et al. (2011) The Effectiveness of RNAi in Caenorhabditis elegans Is Maintained during Spaceflight. PLoS ONE 6(6): e20459. https://doi.org/10.1371/journal.pone.0020459 Editor: Anne C. Hart, Brown University, United States of America Received: February 17, 2011; Accepted: April 21, 2011; Published: June 1, 2011 Copyright: © 2011 Etheridge et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Funding: This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, the Japan Society for the Promotion of Science, and “Ground-Based Research Announcement for Space Utilization” promoted by the Japan Space Forum. TE was supported by the Medical Research Council UK (G0801271). NJS was supported by the National Institutes of Health (NIH NIAMS ARO54342). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing interests: The authors declare that they have no competing interests. Advanced Engineering Services Co. Ltd. has a contract with the Japan Aerospace Exploration Agency. They provided support and integrated this spaceflight experiment, and have no commercial purpose in this study. Advanced Engineering Services Co. Ltd. employs Ms Hashizume, and they approve her authorship on this manuscript. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.

Introduction The RNA interference (RNAi) machinery regulates posttranscriptional gene expression by using small (∼20 nucleotide long) non-coding double-stranded RNA (dsRNA) molecules, in combination with nuclease-containing argonaute complexes, to sequence-specifically silence target mRNAs. Since its discovery [1] RNAi technology has emerged as a promising tool for combating a variety of pathologies. Despite technical difficulties surrounding the effective delivery of dsRNA to diseased tissues, rapid progress has been made towards utilising this technique as a therapeutic over recent years. Indeed, more than a dozen clinical trials are currently underway employing RNAi to target illnesses ranging from cancer to asthma [2], [3]. One currently unexplored use for RNAi technology is within the space (microgravity) environment. A primary aim of the world's space agencies is to send humans to other planetary bodies such as Mars. However, preventing attainment of this goal is the frequent occurrence of various (patho)physiologic adaptations during spaceflight, which may be detrimental for crew health and mission performance. For example, decreases in skeletal muscle mass occur during spaceflight [4]–[6] to levels which are sufficient to impair contractile function [4] and rehabilitation [7]. Loss of bone mass also occurs with 92% of crewmembers experiencing decreases of 5 to 10% [4], [8]. Furthermore, indirect measures of metabolism indicate an increased reliance on glucose utilisation and decreased fat oxidation as a fuel source (reviewed in [9], [10]), which may negatively affect physical performance during extra-vehicular activities requiring prolonged energy expenditure. Finally, T lymphocytes harvested and cultured from crew members display a lowered ability to activate in response to mitogens [11] and also increases in chromosomal aberrations [12], suggesting impaired immune function which, if persistent over longer flights, may pose a serious health risk. Therefore, in order to minimise the inherent risks associated with embarking on long-term deep space explorations, effective countermeasures to these (mal)adaptations must be developed. Drug-based therapies are limited in spaceflight by their short shelf life due to radiation but RNAi may circumvent this disadvantage due to simple and cheap production of dsRNA in flight. However, a number of factors unique to the space environment render the efficacy of RNAi during spaceflight in question. First, total muscle RNA content is lowered after just 7 days spaceflight in LEO [13]. Thus, because the biogenesis of small RNAs is an integral level of RNAi regulation [14] and since the potency of RNAi is amplified by the replication of cellular RNA [15] it is possible that the RNAi machinery may malfunction in space. Second, RNA is less-stable than DNA and may, therefore, be more susceptible to damage by increased radiation in space which again may reduce the effectiveness of RNAi. Third, RNAi evolved as an immune surveillance system whereby malicious genetic material in the form of viruses and transposons are rapidly targeted for destruction [16]. Since T lymphocytes demonstrate impaired activation and increased chromosome aberrations in space [11], [12], and the transcription of genes integral to effective T-cell immune responses is suppressed [17], it may be logical to hypothesise that the RNAi immune response may also be specifically altered by spaceflight, perhaps in the form of reduced mRNA transcription for components of the RNAi machinery. Indeed, UV radiation significantly affects the mRNA expression of major components of RNAi silencing processes in plants [18]. Therefore, before the space agencies can begin to commit the large sums of money necessary to investigate therapeutic strategies during spaceflight, an important initial step is to demonstrate the efficacy of RNAi in this unique environment. Since the nematode Caenorhabditis elegans (C. elegans) was the first animal in which RNAi was demonstrated [1] and because we have established C. elegans as an in vivo model organism for understanding the effects of spaceflight [19]–[22] we tested the efficacy of RNAi in C. elegans during spaceflight. The aim of this experiment was, therefore, to extend the use of C. elegans to determine whether the RNAi machinery continues to function normally during spaceflight. We report for the first time the stable expression of microRNAs and mRNA of genes encoding for components of the RNAi machinery during spaceflight. We also show that RNAi treatment in space induces alterations in target protein expression and localisation that are not different from ground controls. Furthermore, treatment with RNAi against lysosomal enzymes during spaceflight prevents the degradation of muscle proteins on return to Earth. Thus, RNAi presents a viable option for targeted therapeutic strategies onboard future long-term manned space explorations.

Discussion The incidence of spaceflight-induced (patho)physiological adaptations is a major obstacle preventing long-term space exploration. RNAi may provide an effective strategy for therapy, though validation of this technique in the unique space environment is initially required. Here we report for the first time that the RNAi machinery functions as effectively during 4 and 8 d spaceflight as it does on Earth, as evidenced by normal expression of genes encoding for the RNAi machinery and of microRNAs, comparable patterns of GFP transgene abnormalities with RNAi treatment, and inhibition of α-actin protein degradation with lysosome-targeting RNAi in both spaceflight and ground control conditions. The finding that expression of genes involved in the RNAi apparatus (e.g. Dicer, Argonaute and PIWI) is normal during spaceflight indicates that the RNAi machinery maintains the capacity to function normally. Thus, earlier reports of reduced global RNA synthesis after 7 d spaceflight [13] do not appear to be reflected at the level of mRNA transcription, at least of genes coding for RNAi components. Additionally, we report here that the expression of 228 of the 232 microRNAs analysed is unaffected in spaceflight samples. It appears therefore that factors unique to spaceflight, for example microgravity and increased radiation exposure do not impair cellular ability to recognise and initiate gene silencing in response to both exogenous and endogenous genetic material. We also demonstrate that treatment with gfp RNAi in space causes reduced gonad GFP expression to levels comparable to those found in Earth-based controls. GFP expression was, however, normal in animals fed a vector control, therein excluding the possibility that lowered protein synthetic capacity in space [19] may have influenced GFP levels under RNAi conditions. Thus, assuming identical rates of protein degradation in RNAi and vector control conditions, the observed reduction of GFP levels can be attributed to actions of the RNAi machinery. Furthermore, rbx-1 RNAi induced abnormal nuclear histone::GFP localisation within the gonad in both spaceflight and ground controls. Combined, these results indicate that not only is expression of genes involved in RNAi normal but that the protein products of these genes continue to function normally in spaceflight. Thus, spaceflight does not induce negative regulatory post-transcriptional or post-translational modifications that impair the efficiency of RNAi. Finally, the efficacy of RNAi in space is illustrated by the inhibition of muscle-specific protein (α-actin) degradation by asp-4 and asp-6 RNAi treatment, despite virtual total loss of α-actin levels in vector control animals. Thus, cathepsin RNAi administered during spaceflight effectively silences lysosomal proteolytic activity. Furthermore, it is apparent that spaceflight per se does not have large negative effects on lysosomal proteases since degradation of α-actin occurred in the vector control condition. This is also, to our knowledge, the first report that RNAi can be used to block the degradation of muscle proteins on Earth and in space. Because loss of muscle mass implies an increase in the degradation of pre-existing proteins, this result indicates that RNAi may be developed to combat conditions of muscle wasting both on Earth and in space. Taken together, these results demonstrate that, despite reports of impaired T cell function during spaceflight aboard the International Space Station [11], [12], the RNAi immune response is unaffected at the level of both mRNA expression and protein function. Demonstration that this fundamental immunological process is preserved is especially important within the space environment. Enhanced pathogenic virulence in space flown bacteria and increased microbe growth rates [25] render it vital that cells retain their ability to cope with increased exposure to virulent microbes, and indicates that crew member health in response to such stressors may be sustained on long-term exploratory missions. These experiments also show that RNAi works effectively in at least two tissues; muscle and the gonad. Muscle is a key site for many of the potentially negative consequences of spaceflight to crew member health; for example muscle wasting and altered metabolism towards increased glucose utilisation. The gonad is a primary site for the effects of increased radiation-induced DNA damage and subsequent heritability of genetic defects. Thus, application of RNAi in these tissues may represent a viable therapeutic possibility for future missions to overcome these problems. It is also likely, in light of the lack of change in global mRNA expression of the RNAi apparatus, that RNAi may be as effective in other tissues, therein promoting the use of RNAi to combat a large range of pathologies in space. In conclusion, we report for the first time the efficacy of RNAi during spaceflight within multiple tissues. However, whether this is true outside of Low Earth Orbit where the effects of radiation are increased is currently unknown, though C. elegans provides a practical and cost-effective model organism for incorporation on future unmanned deep space explorations in which to answer this, and other, questions of biological importance. Nevertheless, RNAi presents a potential therapeutic strategy for combating deleterious spaceflight-induced adaptations, for maintained crew health and mission performance. Indeed, we show that protein degradation; a key element underlying muscle wasting, can be prevented by the application of RNAi against proteolytic enzymes on Earth and in space. As such, achieving long-duration explorations of deep space may be made more feasible through the use of RNAi technology to overcome the numerous threats posed to human health by prolonged exposure to the space environment.

Materials and Methods Nematode and bacteria preparation Two developmental stages of C. elegans were cultured for these experiments; L1 and dauer larvae. To provide L1 larvae nematode eggs were prepared using the alkaline bleach method with 0.5 N KOH and 1.0% NaClO. After overnight incubation in M9 buffer containing 5 mg/L cholesterol at 20°C, the hatched L1 larvae were used for the space experiment. L1 larvae were prepared from the strain AZ212 (ruIs32; unc-119 (ed3); [26]), whose integrated array is pAZ132 (pie-1::GFP::histone H2B fusion and unc-119 subclone). AZ212 GFP signals are revealed in the nuclei of oocytes and eggs. To provide dauer larvae animals were cultured according to the protocol [27] with the exception that animals were cultured on 8× peptone NGM agar plates. Dauer animals were prepared from the strain PD55 (tra-3(e1107)IV; ccIs55V) whose integrated transgene ccIs55 consists of 58- portions of wild-type unc-54 (muscle myosin heavy-chain) gene, fused in to the lacZ gene of E. coli, followed by a 38-terminal portion of the unc-54 gene. The unc-54::lacZ fusion encodes a 146-kDa polypeptide. Double stranded RNA of gfp (gfp fragment of pGFP U17997 (Clonthech) digested with HindIII and EcoRI), rbx-1 [23], asp-4 [24] and asp-6 (Ahringer library, clone V-5N20) genes were synthesized in Escherichia coli HT115 (DE3) with Litmus 28 plasmid vector in vivo system [23]. The vector control used was Escherichia coli HT115 (DE3). E. coli bacterial feeds were cultured in S basal medium to an OD600 of approximately 3.5. Experimental design A full description of the experimental procedures and flight hardware, including illustrations, employed on this experiment can be found in [28]. We tested three experimental conditions in each culture: ground control, 1G (control) centrifuge onboard the International Space Station (ISS) and micro-gravity samples onboard ISS. Briefly, for the microarray gene expression and microRNA expression experiments N2 wild type L1 larvae were used. For the gfp and rbx-1 RNAi experiments AZ212 L1 larvae were used. For the asp-4 and asp-6 RNAi experiment PD55 dauer larvae were used. All larvae were maintained in stasis within S basal medium until initiation of the experiment. The experiment was activated once onboard the ISS by reintroducing animals to food. All experiments were carried out under temperature controlled conditions in the Cell Biology Experiment Facility (CBEF) within the KIBO module. Cultures for microarray analysis were grown for 8 d. Cultures for microRNA expression analysis were grown for 4 d and 8 d. Cultures for RNAi treatment experiments were grown for 4 d. Experiments were stopped by first observing the animals by light microscopy and then by freezing with subsequent storage at −80°C in MELFI. Microscopy at the end of culturing confirmed that the 4 day cultures grew to adulthood as the first generation for both the L1 and dauer cultures, and that the 8 day cultures grew to a second generation of adulthood. Microarray and microRNA assay Flight samples were thawed on ice with M9 buffer containing 0.05% gelatine, and approximately 103 adult hermaphrodites were collected in each experimental condition by picking under stereo microscopy or by sedimentation on ice. Total RNA was isolated with TRIzol Reagent (Invitrogen). Global gene expression and entire microRNA expression were analyzed using the Agilent Caenorhabditis elegans Oligo Microarray 22K (Agilent) and Filgen® Array miRNA Caenorhabditis elegans 232 probes (Filgen), respectively. Biological triplicates were used for the global gene expression array experiments, and these were each analysed over six microarrays. All global gene expression and microRNA data are MAIME compliant and deposited in the gene expression omnibus (GEO) database (accession numbers GSE27338 and GSE27288 for global gene expression and microRNA data, respectively). In the microRNA expression analysis, we compared the expression data between two groups: micro-gravity samples (4 d and 8 d) and controls (4 d and 8 d ground control and 1 G centrifuge onboard ISS). All statistical analyses were carried out by one-way ANOVA with significance set at P<0.05. Fluorescent light microscopy Flight samples were thawed on ice with M9 buffer containing 0.05% gelatine, and developed adult hermaphrodites plus eggs laid were picked onto HTC Super Cured ® slides (Thermo Scientific). GFP visualization was performed under constant excitation light and the same exposure period for fluorescence with a fluorescent microscope (BX51; Olympus) and a CCD camera (DP70; Olympus). Immunoblotting Upon return to Earth, developed dauer animals were thawed on ice in the presence of a protease inhibitor cocktail (Complete Mini protease inhibitor tablet; Roche Diagnostics, Mannheim, Germany) in 15 ml tubes. Samples were then pelleted by centrifugation at 13,000×g for 10 min at 4°C and the supernatant removed to leave ∼1 ml. Samples were then transferred to 1.5 ml tubes and spun at 13,000×g for 3 min. The supernatant was then removed to leave 400 µl, the pellet homogenised and 200 µl 3×Laemmli buffer added. Samples were then boiled for 5 min and stored at −20°C until analysis. Samples were thawed on ice, vortexed thoroughly and centrifuged at 13,000×g for 3 min at 4°C to pellet any residual E. coli bacteria. Samples (5 µl) were loaded onto a precast 26-well 12% sodium dodecyl sulfate polyacrylamide electrophoresis gel (Criterion XT Bis-Tris; Bio-Rad, Hemel Hempstead, UK) and ran at 200 V for 1 h. After equilibration in transfer buffer for 15 min, the gel was transferred on ice at 100 V for 45 min to a methanol pre-wetted 0.2 µm Immobilon PVDF membrane (Millipore, Billerica, MA). Next, the membrane was blocked in 5% (w/v) BSA in TBS-T (Tris Buffered Saline and 0.1% Tween-20) for 1 h at room temperature and then incubated overnight at 4°C in primary β-actin antibody (New England Biolabs, UK) at a 1∶3000 dilution in 5% (w/v) BSA in TBS-T. The following morning the membrane was washed (3×5 min) in TBS-T and then incubated in anti-rabbit secondary antibody (New England Biolabs, UK) at a 1∶2000 dilution in 5% BSA / TBS-T for 1 h at room temperature. After further washes (3×5 min) in TBS-T the membrane was developed using Immunstar ECL reagent (Bio-Rad, Richmond, CA) for 5 min and the protein bands visualised on a Chemidoc XRS system (Bio-Rad, Hercules, CA). The membrane was subsequently washed (rapidly×2, then 3×5 min) in TBS-T before stripping antibody-bound proteins in neat reagent (Thermo Scientific, Rockford, IL) for 15 min. The membrane was then re-probed with primary α-actin antibody (Sigma-Aldrich, St. Louis, MO) at a 1∶3000 dilution in 5% (w/v) BSA in TBS-T overnight at 4°C. The next day washes, secondary incubation and visualisation were performed as above. This method was repeated another two times with different primary antibodies against α-actin (Invitrogen, Paisley, UK; DSHB, Iowa, US) for a total of three Western blots. Peak density from the three runs was statistically analysed by two-way repeated measures ANOVA with the level of significance set at P<0.01.

Acknowledgments We are grateful to the entire crew of the C. elegans RNAi space experiment (CERISE) for operation in STS129, STS130 and the ISS Kibo module. The CERISE was organized with the support of the Japan Aerospace Exploration Agency. We thank the Caenorhabditis elegans Genetic Center for kind supply of the GFP-fusion strains and Lew Jacobson, University of Pittsburgh for the asp-4 RNAi construct. We also extend thanks to Freya Shephard who prepared some of the dauer animals used in these experiments.

Author Contributions Conceived and designed the experiments: TE KF A. Higashibata NJS A. Higashitani. Performed the experiments: TE KN TH CM TS A. Higashibata NJS A. Higashitani. Analyzed the data: TE KN TH A. Higashibata NJS A. Higashitani. Contributed reagents/materials/analysis tools: HS KF TY. Wrote the paper: TE NJS A. Higashitani.